CzeekV インデックス 活用事例・実践,研究報告など、お役立ち情報をシェアします

論文・技術情報追加のお知らせ

• 論文・技術情報追加のお知らせ

  2025年2月23日～2025年3月1日の間に収集した論文情報を追加しました。

  1. Mining and analysis of dizziness adverse event signals in postoperative analgesia patients based on the FDA adverse event reporting system database.

  術後鎮痛薬、特にアミトリプチリンとクローンザゼパム、めまいリスク増加

  対象DB：FAERS

  2. Real-world pharmacovigilance investigation of imipenem/cilastatin: signal detection using the FDA Adverse Event Reporting System (FAERS) database.

  イミペネム/シラスタチン、高齢者に神経系AEs注意

  対象DB：FAERS

  3. Disproportionality analysis of vibegron-associated adverse events using the FDA adverse event reporting system (FAERS): a real-world pharmacovigilance study.

  バイブグロンは尿路・消化器系AEsに注意

  対象DB：FAERS

  4. Safety analysis of romiplostim, eltrombopag, and avatrombopag post-market approval: a pharmacovigilance study based on the FDA Adverse Event Reporting System.

  エルトロンボパグは肝障害リスク高、注意喚起

  対象DB：FAERS

  5. Second-Generation Antipsychotic-Associated Serious Adverse Events in Women: An Analysis of a National Pharmacoepidemiologic Database.

  女性はSGA使用でTdPリスクと重症度増

  対象DB：FAERS

  6. Severe Acute Respiratory Failure Associated With Trimethoprim/Sulfamethoxazole Among Adolescent and Young Adults: An Active Comparator-Restricted Disproportionality Analysis From the FDA Adverse Event Reporting System (FAERS) Database.

  TMP-SMX使用で若年層の急性呼吸不全リスク増

  対象DB：FAERS

  7. Fosfomycin-associated adverse events: A disproportionality analysis of the FDA Adverse Event Reporting System.

  ホスホマイシン使用で消化器障害などを確認

  対象DB：FAERS

  8. Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system.

  ウパダシチニブで新たな有害事象シグナルを確認

  対象DB：FAERS

  9. Diabetic Ketoacidosis and the Use of New Hypoglycemic Groups: Real-World Evidence Utilizing the Food and Drug Administration Adverse Event Reporting System.

  SGLT2阻害薬でDKAリスクが最高、近年減少

  対象DB：FAERS

  10. Amlodipine-Associated Angioedema: An Integrated Pharmacovigilance Assessment Using Disproportionality and Interaction Analysis and Case Reviews.

  アムロジピンで血管浮腫リスク、特定RAAS阻害薬と関連

  対象DB：FAERS

  11. Post-marketing safety surveillance of Amivantamab: a real world study based on the FDA adverse event reporting system.

  アミバンタマブの有害事象は23臓器系に分布

  対象DB：FAERS

  12. Haemorrhage-related adverse events profles of lenvatinib and pembrolizumab alone or in combination: a real-world pharmacovigilance study based on FAERS database.

  レンバチニブ＋ペムブロリズマブ併用で出血リスク増加

  対象DB：FAERS

  13. Oseltamivir-induced hepatotoxicity: A retrospective analysis of the FDA adverse event reporting system.

  オセルタミビルは性別・年齢で異なる肝毒性リスクあり

  対象DB：FAERS

  14. Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors.

  AGIs+ICIs併用で出血リスクが増大

  対象DB：FAERS

  15. Safety profiles of sevoflurane in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database.

  小児でセボフルランの新たな有害事象を確認

  対象DB：FAERS

  16. Update of safety profile of levonorgestrel: a disproportionality analysis based on FAERS from 2004 to 2023.

  レボノルゲストレルで新たな有害事象を確認

  対象DB：FAERS

  17. A pharmacovigilance study based on the FAERS database focusing on anticoagulant and hormonal drugs that induce vaginal hemorrhage.

  抗凝固薬やホルモン薬で膣出血リスク増加

  対象DB：FAERS

  18. Real-world study of medication-related osteonecrosis of the jaw from 2010 to 2023 based on Food and Drug Administration Adverse Event Reporting System.

  ビスホスホネートやRANKL阻害剤で顎骨壊死リスク増加

  対象DB：FAERS

  19. Investigating Drug-Induced Thyroid Dysfunction Adverse Events Associated With Non-Selective RET Multi-Kinase Inhibitors: A Pharmacovigilance Analysis Utilizing FDA Adverse Event Reporting System Data.

  非選択的RET阻害剤で甲状腺機能障害のリスク増加

  対象DB：FAERS

  20. The safety assessment of ustekinumab on psoriasis and psoriatic arthritis: A real-world analysis based on the FDA adverse event reporting system database.

  USTで感染症・肝胆疾患・腫瘍のリスク増加

  対象DB：FAERS

  21. Endocrine adverse reactions of tyrosine kinase inhibitors in combination with immune checkpoint inhibitors.

  TKI+ICI併用で内分泌有害事象が増加

  対象DB：FAERS

  22. Risk of acute renal failure associated with combined use of SGLT2 inhibitors and potentially nephrotoxic drugs: an epidemiological surveillance study based on the FDA adverse event reporting system (FAERS).

  SGLT2阻害薬と併用薬で急性腎障害リスク

  対象DB：FAERS

  23. A comprehensive exploration of adverse reactions to lapatinib: a disproportionate analysis based on the FAERS database.

  ラパチニブは消化器・皮膚毒性に注意

  対象DB：FAERS

  24. A disproportionality analysis of surgical site infections across multiple sclerosis disease modifying therapies.

  MS治療薬でSSIリスク増、特に50歳以上

  対象DB：FAERS

  25. Safety evaluation of ILaris: a real-world analysis of adverse events based on the FAERS Database.

  Ilarisの有害事象に肺血栓や肝腫大あり

  対象DB：FAERS

  26. Safety of dual orexin receptor antagonists: a real-world pharmacovigilance study.

  DORAの有害事象は睡眠麻痺や不眠が多い

  対象DB：FAERS

  27. Real-world safety analysis of deutetrabenazine post-marketing: a disproportionality study leveraging the FDA Adverse Event Reporting System (FAERS) database.

  デューテトラベナジンは初月に有害事象報告が多い

  対象DB：FAERS

  28. Characteristics and patterns of adverse event reports in the Japanese Adverse Drug Event Report database over two decades (2004-2023): Exploring findings on sexes and age groups.

  JADERの有害事象報告は70歳以上と20-49歳女性で多い

  対象DB：JADER

  29. Optimal follow-up duration of cardiac function tests in patients treated with trastuzumab: an analysis using the Japanese Adverse Drug Event Report (JADER) database.

  トラスツズマブ心毒性は中央値4.5カ月、18カ月で評価終了可能

  対象DB：JADER

  30. Ventral capsule/ventral striatum deep brain stimulation versus anterior capsulotomy in treatment-resistant major depression: A systematic review and data analysis.

  VC/VS-DBSとACAPSはTRDに有効も副作用あり

  対象DB：JADER

  31. The UK's Early Access to Medicines Scheme 10 years on: an evaluation using publicly available data.

  EAMS薬の47%で副作用報告が増加

  対象DB：EudraVigilance

  32. The Assessment of the Safety Profile of Selective Serotonin Reuptake Inhibitors Versus Other Antidepressants: Drug-Drug Interaction Insights from EudraVigilance.

  セルトラリンの薬物相互作用報告が最多

  対象DB：EudraVigilance

  33. Real-World Evidence of Bevacizumab and Panitumumab Drug Resistance and Drug Ineffectiveness from EudraVigilance Database.

  ベバシズマブとパニツムマブの耐性・無効例を解析

  対象DB：EudraVigilance

  34. Analysis of Reporting Trends of Serious Adverse Events Associated With Anti-Obesity Drugs.

  セマグルチドの重篤な有害事象報告が増加傾向

  対象DB：EudraVigilance

  35. Cardiovascular safety profile of JAK inhibitors and ethnic factors in Asians: A signal detection study using the Global ICSR (WHO-UMC VigBase) database.

  JAK阻害薬はアジア人で血栓リスク増大

  対象DB：VigiBase

  36. Epidemiology of reported serious adverse drug reactions due to anti-infectives using nationwide database of Thailand.

  抗感染薬による重篤な副作用は高齢者でリスク増大

  対象DB：VigiBase

  37. Disproportionality analysis from World Health Organization data on migraine-specific medications and cerebrovascular diseases.

  片頭痛薬の一部は脳血管疾患リスクを増加させる可能性

  対象DB：VigiBase

  38. Lung toxicity related to trimethoprim/sulfamethoxazole: pharmacovigilance data review.

  ST合剤は稀だが重篤な肺障害を引き起こす可能性

  対象DB：FPVD,VigiBase

  39. Association between hospital case volume and mortality in pediatric sepsis: A retrospective observational study using a Japanese nationwide inpatient database.

  小児敗血症の院内死亡率は高症例病院で低い

  対象DB：DPC

  40. The epidemiology of fifth metatarsal fracture surgeries in Japan using nationwide hospital claim database.

  日本の第5中足骨骨折手術は高校生と高齢女性に多い

  対象DB：DPC

  41. Trends in Kampo Medicine Usage as Supportive Care During Anticancer Drug Treatment in Japanese Patients: A Nationwide Cohort Analysis from Fiscal Years 2015 to 2021.

  がん治療中の漢方薬使用は減少傾向にある

  対象DB：JMDC

  42. A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study.

  2型糖尿病治療薬の最適選択を予測するモデルを開発

  対象DB：CPRD

  43. Identification of individual-level clinical factors associated with increased risk of death during heatwaves: a time-stratified case-crossover study using national primary care records in England.

  熱関連死亡リスク因子を英国の診療記録で解析

  対象DB：CPRD

  44. Changes in serum creatinine during and after pregnancy in female patients with or without chronic kidney disease: an observational study in UK primary care data.

  妊娠中後の血清クレアチニン変化を検討

  対象DB：CPRD

  45. Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study.

  GLP-1受容体作動薬と自殺リスクに関連なし

  対象DB：CPRD

  46. Maternal postpartum six-week check and short-term health outcomes for women with hypertensive disorders in pregnancy: An observational study using the Clinical Practice Research Datalink (CPRD).

  妊娠高血圧女性の産後診察率に格差

  対象DB：CPRD

  47. Greenhouse gas emissions associated with severe asthma care in the United Kingdom.

  重症喘息管理はGHG排出削減に貢献

  対象DB：CPRD

  48. Development of an Adverse Event Reporting Form for Herbal Medicine: A Delphi Expert Consensus Study.

  ハーブ薬の有害事象報告書を専門家が開発

  対象DB：KAERS

  タグ:

  • お知らせ
  • 論文

• お問合わせ

  お問合わせ

  検索

  サイト内検索・論文検索

  

  検索

  サイト内 論文

  キーワード

  PubmedID
  Abstract
  Title
  Journal
  Date (PubMed追加日)	～
  Author
  タクソノミー検索	タクソノミー検索 CAERS CARD CPRD CVAR CVARD DeSC DPC EHR ESP-VAERS EudraVigilance FAERS Fibroblasts FPVD GPRD Ionizing JADER JMDC KAERS KIDS-KAERS KIDS-KD MDV NDB Nickel Pharmacoepidemiology Radiation RWE THIN Unknown VAERS VigiBase インフォメーション スコア値 スコア指標 総合ランキング 閾値

  

  メルマガ登録

  購読申し込み